At present, vaccine candidates by Bharat Biotech, Serum Institute of India (Oxford University-AstraZeneca), and Zydus Cadila are under advanced stages of trials.
Three COVID-19 vaccine candidates, including two indigenous ones, are in different phases of development in India.
The drug will be made available across India through the group’s strong distribution chain reaching out to government and private hospitals treating Covid patients, announced Zydus.
Priced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.
Principal Investigators involved in the vaccine trial said that it will take at least a month for the first phase of the trial to be completed.
Leading vaccine major Serum Institute of India has said that it is hoping to develop a COVID-19 vaccine by the year-end.
The company has received final approval to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement.
In the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing.
The company said it will conduct a study to evaluate the efficacy and safety of Desidustat tablets for the management of COVID-19 patients.
Phase 1 trials are small-scale, usually involving few participants, to assess whether the vaccine is safe for humans.
ICMR DG Dr Balram Bhargava said that the subject enrollment should be completed by July 7 as the government is looking to launch the vaccine by August 15.